Assembly Biosciences, Inc. ASMB
Set alert
20.13 USD -0.73 -3.50%
At close · Oct 30
20.13 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
19.98 Day range 21.00
19.67 52-week range 38.50
- YTD
- -40.81%
- 1 year
- -33.17%
- Open
- 20.86
- Prev close
- 20.86
- Mkt cap
- 409.86M
- Vol
- 136.87K
- Avg vol
- 291.99K
- EPS
- 1.04
- P/E
- 19.36
- Div yield
- 0.00%
More statistics
- Low
- 19.98
- High
- 21.00
- Forward P/E
- -2.12
- Beta
- 0.59
- Short ratio
- 0.41
- Inst. own
- 18.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 27, 2024
- 50-d avg
- 16.31
- 200-d avg
- 15.02
- 1y target
- 35.50
2Y chart
Events in this range
- Nov 7, 2024Earnings: -1.51; estimate -2.02; surprise 25.25%
Signals (95)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 26, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| RSI: Oversold | Jun 10, 2026 | 4 months ago |
| RSI: Oversold | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 6 months ago |
| SMA: Bullish | May 5, 2026 | 6 months ago |
| MACD: Buy Signal | May 5, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 22, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 27, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 27, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 26, 2026 | 7 months ago |
| SMA: Bullish | Mar 20, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| SMA: Bullish | Mar 4, 2026 | 8 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
| SMA: Bullish | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 4, 2026 | 9 months ago |
| RSI: Oversold | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 2, 2026 | 10 months ago |
| SMA: Bullish | Dec 31, 2025 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Dec 24, 2025 | 10 months ago |
| SMA: Bearish | Dec 23, 2025 | 10 months ago |
| SMA: Bullish | Dec 19, 2025 | 10 months ago |
| SMA: Bearish | Dec 17, 2025 | 10 months ago |
| MACD: Sell Signal | Nov 28, 2025 | 11 months ago |
| RSI: Overbought | Nov 21, 2025 | 11 months ago |
| RSI: Overbought | Nov 12, 2025 | 11 months ago |
| RSI: Overbought | Oct 17, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 9, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 3, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 23, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 28, 2025 | 1 year ago |
| RSI: Overbought | Aug 8, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 7, 2025 | 1 year ago |
| RSI: Overbought | Jul 7, 2025 | 1 year ago |
| RSI: Overbought | Jul 2, 2025 | 1 year ago |
| RSI: Overbought | Jun 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 23, 2025 | 1 year ago |
| RSI: Overbought | Jun 20, 2025 | 1 year ago |
| RSI: Overbought | Jun 16, 2025 | 1 year ago |
| RSI: Overbought | Jun 10, 2025 | 1 year ago |
| RSI: Overbought | Jun 6, 2025 | 1 year ago |
| RSI: Overbought | Jun 4, 2025 | 1 year ago |
| RSI: Overbought | May 2, 2025 | 1 year ago |
| SMA: Bullish | Apr 29, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 6, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 26, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 26, 2024 | 1 year ago |
Key statistics
- Market cap
- 93.56M
- Enterprise value
- 3.57M
- Trailing P/E
- 0.00
- Forward P/E
- -2.12
- PEG ratio
- 0.00
- Price / sales
- 4.36
- Price / book
- 1.96
- EPS (TTM)
- -6.89
- Beta
- 0.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -212.33%
- Revenue (TTM)
- 21.48M
- Revenue growth
- 0.00%
- Free cash flow
- 5.50M
- Total cash
- 109.22M
- Total debt
- 1.75M
- Return on equity
- -101.77%
- Shares outstanding
- 6.36M
- Short % of float
- 0.38%
- 50-day average
- 16.31
- 200-day average
- 15.02
Analyst view
Consensus: none
Price target (mean) 35.50 +76.4% upside
Now 20.13
- Target (low)
- 35.00
- Target (mean)
- 35.50
- Target (high)
- 36.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 27, 2024
Expected Mar 27, 2024. Consensus EPS estimate -1.75.
Financials — quick view
ASMB Revenue — quarterly 0
ASMB Net income — quarterly -3.86M
ASMB EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -2.02 | -1.51 | +0.51 | +25.25% |
| Aug 8, 2024 | Jun 1, 2024 | -2.96 | -1.98 | +0.98 | +33.11% |
| May 8, 2024 | Mar 1, 2024 | -2.74 | -1.66 | +1.08 | +39.42% |
| Mar 27, 2024 | Dec 1, 2023 | -2.88 | — | — | — |
| Nov 8, 2023 | Sep 1, 2023 | -2.76 | -3.24 | -0.48 | -17.39% |
| Aug 9, 2023 | Jun 1, 2023 | -3.48 | -3.84 | -0.36 | -10.34% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 20, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Jun 13, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Apr 1, 2024 | HC Wainwright & Co. | reit | — | Neutral |
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- assemblybio.com
News
- Assembly Biosciences Doses First Two Patients In Its Phase 2 Clinical Trial Of ABI-6250 To Treat Chronic Hepatitis Delta Virus Infection
- Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
- Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB)
- Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026
- Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
- Best Momentum Stocks to Buy for September 17th
- New Strong Buy Stocks for September 17th
- Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
- Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
- Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
Your note
Sign in to keep a note on ASMB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BJORKQUIST JEANETTE M | Officer | Sale | May 22, 2024 | 3,142 |
| DELANEY WILLIAM E IV | Officer | Stock Award(Grant) | Apr 28, 2024 | 16,109 |
| GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 16, 2024 | 1,268,970 |
| MCHUTCHISON JOHN G | Director | Sale | May 22, 2024 | 19,104 |
| OKAZAKI JASON A | Chief Executive Officer | Sale | Oct 2, 2024 | 14,904 |
| SCHORNSTEIN ALEXANDER | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 24, 2024 | 728,113 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 5.57% | 354,000 | 5.21M | Sep 29, 2024 |
| Vanguard Group Inc | 3.15% | 200,458 | 2.95M | Sep 29, 2024 |
| Blackrock Inc. | 1.21% | 77,108 | 1.14M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.03% | 65,624 | 965.99K | Sep 29, 2024 |
| Acuitas Investments LLC | 0.98% | 62,315 | 917.28K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.74% | 47,034 | 692.34K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.81% | 114,782 | 1.69M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.04% | 66,356 | 976.76K | Sep 29, 2024 |
| Federated Hermes MDT Mid Cap Growth Fund | 0.40% | 25,394 | 373.80K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 23,660 | 348.27K | Oct 30, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 0.28% | 17,723 | 260.88K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 13,750 | 202.40K | Sep 29, 2024 |